Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Dexcom UK logo — The future of Continuous Glucose Monitoring is here.

Dexcom UK

The future of Continuous Glucose Monitoring is here.

Founded 1999 United Kingdom Edinburgh, United Kingdom 27 employees Post-IPO Debt Total: $2.16B Health Care

General Information

Company Name Dexcom UK
Founded Year 1999
Location United Kingdom Edinburgh, United Kingdom
Employees 27
Industries Health Care
Funding Stage Post-IPO Debt
Business Model B2B2C, D2C, E Commerce
Revenue Model Product Sales, Pay As You Go
Social

BounceWatch is an independent company data service, not affiliated with Dexcom UK. To contact Dexcom UK, visit uk.provider.dexcom.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Feature Release Sep 25, 2026

Dexcom UK has launched a new feature for its Dexcom G7, which now connects with Tandem Mobi, the world’s smallest durable AID system.

New Partnership Sep 23, 2026

Dexcom UK has announced a joint symposium with Sanofi at EASD 2026 to discuss CGM and basal insulin in clinical care.

Event Participation Sep 21, 2026

Dexcom UK is set to participate as an exhibitor at EASD 2026 in Milan, inviting attendees to learn about personalized guidance and try products.

Get alerts when Dexcom UK shows new signals

About Dexcom UK

Dexcom UK, founded in 1999, is a prominent player in the Health Care industry, specializing in real-time Continuous Glucose Monitoring (rtCGM) systems for individuals managing diabetes with insulin. Headquartered in the United Kingdom, the company has made significant strides in transforming diabetes care through innovative rtCGM technology.

The company's slogan, "The future of Continuous Glucose Monitoring is here," encapsulates its mission to enhance the outcomes for patients, caregivers, and healthcare professionals by providing real-time data and empowering self-management.

Dexcom UK is committed to improving diabetes management, with its technology facilitating better support from healthcare professionals. The company's success is underscored by a substantial $1.00B Post-IPO Debt investment made on May 2, 2023.

Taxonomy: Continuous Glucose Monitoring, Real-time CGM Systems, Diabetes Care, Diabetes Management, Glucose Sensing Technologies, Healthcare Professional Support, Patient Outcomes, Caregiver Support, Clinician Empowerment, Decision Support, Mobile Software, Sensor Technology, Implantable Sensors

Services & Products

Continuous glucose monitoring systems
Diabetes management tools
Digital health data applications
Free sensor trials

Target Customers

People with type 1 diabetes People with type 2 diabetes Hypo Unaware Patients Pregnant Women with Diabetes Children with Diabetes Healthcare Providers NHS Funded Patients

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Debt $1.00B -
02 May 2023
Post IPO Debt Undisclosed -
12 May 2020
Post IPO Equity $750.00M -
01 Nov 2018
Post IPO Debt $350.00M -
09 May 2017
Post IPO Equity $7.23M -
02 May 2016
Post IPO Equity $3.96M -
12 Apr 2012
Series D $22.50M 4
Canaan Partners Warburg Pincus St. Paul Venture Capital
Canaan Partners, Warburg Pincus +2
06 Jan 2005
Series C $30.00M 6
Canaan Partners St. Paul Venture Capital Fog City Capital
Canaan Partners, St. Paul Venture Capital +4
03 Jun 2002

Latest News

View All
The FDA just picked its first company to sell an unauthorised device to Medicare patients — Thenextweb
The FDA just picked its first company to sell an unauthorised device to Medicare patients
Thenextweb Jul 27, 2026
UPC sees next life sciences case as Guardant sues Sophia Genetics — Juve-patent.com
UPC sees next life sciences case as Guardant sues Sophia Genetics
Juve-patent.com Sep 23, 2025
Digital health companies got pummeled by Wall Street in 2024 as industry adapts to post-Covid slowdo... — Cnbc
Digital health companies got pummeled by Wall Street in 2024 as industry adapts to post-Covid slowdown
Cnbc Dec 24, 2024
Akıllı yüzükler geliştiren Oura, 5 milyar dolar değerleme üzerinden 75 milyon dolar yatırım aldı — Webrazzi
Akıllı yüzükler geliştiren Oura, 5 milyar dolar değerleme üzerinden 75 milyon dolar yatırım aldı
Webrazzi Nov 20, 2024
Dexcom launches first over-the-counter continuous glucose monitor. Here's what it's like — Cnbc
Dexcom launches first over-the-counter continuous glucose monitor. Here's what it's like
Cnbc Aug 26, 2024
Dexcom shares plunge more than 40%, head for worst day on record — Cnbc
Dexcom shares plunge more than 40%, head for worst day on record
Cnbc Jul 26, 2024

Dexcom UK Alternatives & Competitors

View All Alternatives
Dexcom UK vs
Senseonics, Incorporated
Senseonics, Incorporated United States

Advancing the future of diabetes management through innovative technology.

IPO
280 employees
Biotechnology, Hardware
Compare Dexcom UK vs Senseonics, Incorporated
Dexcom UK vs
GlucoSet
GlucoSet Norway

Intensive care monitoring

16 employees
Biotechnology, Health Care
Dexcom UK vs
OneTwo Analytics
OneTwo Analytics Sweden

Creating knowledge from diabetes data, enabling precision medicine and digital transformation in hea...

Venture round
12 employees
Health Care, Medical Devices
Compare Dexcom UK vs OneTwo Analytics
Also compare with: Dexcom UK vs Indigo Indigo View all alternatives

FAQ About Dexcom UK

The future of Continuous Glucose Monitoring is here.
Dexcom UK was founded in 1999.
Dexcom UK is headquartered in Edinburgh, United Kingdom.
Dexcom UK operates in Health Care. Its work centres on Continuous Glucose Monitoring, Real-time CGM Systems, Diabetes Care and Diabetes Management. Its customers include People with type 1 diabetes, People with type 2 diabetes and Hypo Unaware Patients.
Dexcom UK has a B2B2C, D2C and E Commerce business model. Its revenue comes from Product Sales and Pay As You Go.
Dexcom UK has approximately 27 employees.
Dexcom UK has completed 8 funding rounds, raising a total of $2.16B. The latest funding stage is Post-IPO Debt.
Dexcom UK offers: Continuous glucose monitoring systems, Diabetes management tools, Digital health data applications, Free sensor trials.
Top alternatives and competitors to Dexcom UK include Senseonics, Incorporated, GlucoSet, OneTwo Analytics, Bio Conscious Technologies Inc., Ambrosia Systems Inc. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Dexcom UK and Senseonics, Incorporated are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Dexcom UK, https://bouncewatch.com/company/dexcom, updated 26 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes